获取新生物标志物的批准指南:从发现到临床实施
Harriet Feilotter1, Christine Bruce2,3, Eleftherios P Diamandis4
1Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
将分子发现转化为临床实践需要严格的技术和临床验证. 本指南概述了用于商业化分子标记物的关键参数,以及为改善患者护理的监管途径.
科学领域:
- 生物技术是生物技术.
- 临床诊断 临床诊断 临床诊断
- 分子医学是分子医学.
背景情况:
- 将分子发现转化为临床应用是一个复杂的,多步骤的过程.
- 成功的商业化需要大量的计划,时间,精力和财务投资.
- 确保患者受益需要强有力的验证和明确的实施准则.
研究的目的:
- 为商业化分子标记物提供技术和临床验证参数指南.
- 讨论分子测试的监管批准选项.
- 突出基于证据的实施对改善患者护理的重要性.
主要方法:
- 对技术和临床验证参数的审查.
- 讨论监管途径,包括伴随诊断和实验室开发的测试.
- 对实施策略和解释指南的分析.
主要成果:
- 成功的临床整合取决于严格的验证和明确的测试协议.
- 存在多种实现路线,每个路线都有不同的监管考虑.
- 监管部门的批准是黄金标准,但资源密集;实验室开发的测试面临着关于监督的持续辩论.
结论:
- 在临床实施之前,确认临床和分析有效性至关重要.
- 对于测试指示,频率和解释的明确准则对于成功采用至关重要.
- 证明改善患者护理结果对于分子测试的成功实施至关重要.
更多相关视频
07:35Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
相关概念视频
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Preclinical Development: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Products: Biologics, Biosimilars and Interchangeables
Clinically Relevant Drug Product Specifications: Methods of Establishment
